兰瑞肽乙酸盐

• 常用名: 兰瑞肽乙酸盐
• 英文名: Lanreotide acetate
• CAS号: 127984-74-1
• 分子量: 1156.375
• 密度: N/A
• 沸点: N/A
• 分子式: C₅₆H₇₃N₁₁O₁₂S₂
• 熔点: N/A
• 闪点: N/A
• 符号: GHS08
• 信号词: Warning

兰瑞肽乙酸盐用途

Lanreotide is a a synthetic cyclic octapeptide analogue of somatostatin. Lanreotide inhibits the secretion of growth hormone (GH) by binding to pituitary somatostatin receptors, and may inhibit the release of various other hormones, including thyroid stimulating hormone (TSH) and the gastroenteropancreatic hormones insulin, glucagon and gastrin. This agent also decreases circulating total and free insulin-like growth factor 1 (IGF-I). Lanreotide exhibits a high binding affinity for somatostatin receptor 2 (SSTR-2) and a lesser binding affinity for SSTR-5. However, compared to octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

兰瑞肽乙酸盐名称

• 中文名: 兰瑞肽
• 英文名: Somatuline
• 中文别名: 兰瑞肽乙酸盐

兰瑞肽乙酸盐物理化学性质

• 分子式: C₅₆H₇₃N₁₁O₁₂S₂
• 分子量: 1156.375
• 精确质量: 1155.488159
• 外观性状: white to off-white
• 储存条件: ?20°C

兰瑞肽乙酸盐安全信息

• 符号: GHS08
• 信号词: Warning
• 危害声明: H361
• 警示性声明: P281
• 危害码 (欧洲): Xn
• 风险声明 (欧洲): 63
• 安全声明 (欧洲): 36/37
• 危险品运输编码: NONH for all modes of transport

兰瑞肽乙酸盐英文别名

• (4R,7S,10S,13R,16S,19R)-10-(4-Aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxo-2-butanyl]-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-isopropyl-19-{[3-(2-naphthyl)-D-alanyl]amino}-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide acetate (1:1)
• 9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide acetate (salt)
• 1,2-Dithia-5,8,11,14,17-pentaazacycloeicosane-4-carboxamide, 10-(4-aminobutyl)-N-[(1S,2R)-1-(aminocarbonyl)-2-hydroxypropyl]-19-[[(2R)-2-amino-3-(2-naphthalenyl)-1-oxopropyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-7-(1-methylethyl)-6,9,12,15,18-pentaoxo-, (4R,7S,10S,13R,16S,19R)-, acetate (1:1) (salt)
• Somatuline
• (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-{[(2R)-2-amino-3-naphthalen-2-ylpropanoyl]amino}-N-[(1S,2R)-1-carbamoyl-2-hydroxypropyl]-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-(1-methylethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide acetate (salt)
• 9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-carboxamidacetat(salt)
• (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(1S,2R)-1-carbamoyl-2-hydroxypropyl]-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-(1-methylethyl)-19-[(3-naphthalen-2-yl-D-alanyl)amino]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide acetate (salt)
• Somatuline LP
• (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(1S,2R)-1-carbamoyl-2-hydroxypropyl]-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-(1-methylethyl)-19-[(3-naphthalen-2-yl-D-alanyl)amino]-6,9,12,15,18-pe
• lanreotide acetate
• (4R,7S,10S,13R,16S,19R)-10-(4-Aminobutyl)-19-{[(2R)-2-amino-3-naphthalen-2-ylpropanoyl]amino}-N-[(1S,2R)-1-carbamoyl-2-hydroxypropyl]-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-(1-methylethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-carboxamidacetat(salt)
• (4R,7S,10S,13R,16S,19R)-10-(4-Aminobutyl)-19-{[(2R)-2-amino-3-naphthalen-2-ylpropanoyl]amino}-N-[(1S,2R)-1-carbamoyl-2-hydroxypropyl]-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-(1-methylethyl)-6,
• Somatuline LA
• ntaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide acetate (salt)
• Somatuline Autogel
• 1,2-dithia-5,8,11,14,17-pentaazacycloeicosane-4-carboxamide, 10-(4-aminobutyl)-N-[(1S,2R)-1-(aminocarbonyl)-2-hydroxypropyl]-19-[[(2R)-2-amino-3-(2-naphthalenyl)-1-oxopropyl]amino]-16-[(4-hydroxypheny